New combo therapy shows promise for Drug-Resistant lung cancer
NCT ID NCT04606771
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding savolitinib to osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR-mutated, MET-amplified) that has worsened despite osimertinib treatment. About 30 adults will receive either the drug combination or savolitinib with a placebo. The main goal is to see how many patients have their tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
savolitinib and osimertinib (drug combination)
What this could lead to
If it works, this could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to standard therapy.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The combination may not improve outcomes or could cause additional side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Sacramento, California, 95817, United States
-
Research Site
Ciudad de Buenos Aires, C1120AAT, Argentina
-
Research Site
Delhi, 110085, India
-
Research Site
Mumbai, 400053, India
-
Research Site
Taichung, 402, Taiwan
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Taipei, 11217, Taiwan
-
Research Site
Taipei, 235, Taiwan
-
Research Site
Taoyuan City, 333, Taiwan
-
Research Site
Bangkok, 10210, Thailand
-
Research Site
Bangkok, 10300, Thailand
-
Research Site
Bangkok, 10330, Thailand
-
Research Site
Bangkok, 10400, Thailand
-
Research Site
Bangkok, 10700, Thailand
-
Research Site
Hat Yai, 90110, Thailand
-
Research Site
Khon Kaen, 40002, Thailand
-
Research Site
Muang, 50200, Thailand
-
Research Site
Hanoi, 100000, Vietnam
-
Research Site
Hà Nội, 100000, Vietnam
-
Research Site
Ho Chi Minh City, 700000, Vietnam